<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03237455</url>
  </required_header>
  <id_info>
    <org_study_id>0102-17-EMC</org_study_id>
    <nct_id>NCT03237455</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging in High Risk Patients for the Development of Diffuse Idiopathic Skeletal Hyperostosis (DISH)</brief_title>
  <official_title>Magnetic Resonance Imaging in High Risk Patients for the Development of Diffuse Idiopathic Skeletal Hyperostosis (DISH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Chaim Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diffuse idiopathic skeletal hyperostosis (DISH) is a poorly understood, systemic condition&#xD;
      characterized by progressive calcification and ossification of ligaments and entheses. The&#xD;
      current classification criteria allow diagnosing the disease in its late course, when&#xD;
      significant bony overgrowth already involves the vertebral column and the appendicular&#xD;
      skeleton. The research of the pathogenic mechanisms in DISH, is significantly hampered by the&#xD;
      late diagnosis resulting from this definition.Based on recent MRI studies in both axial&#xD;
      spondyloarthritis (axSpA) and in DISH, it seems that changes similar to the classical early&#xD;
      inflammatory changes described in axSpA, can be detected in patients with DISH. We therefore&#xD;
      hypothesize, that patients with metabolic syndrome without radiographic evidence for spinal&#xD;
      DISH, might exhibit early MRI changes. If this hypothesis proves to be correct, early&#xD;
      diagnosis and research of the possible pathogenetic mechanisms at this early stage might be&#xD;
      very rewarding in investigations of the early aberrations of the entheses homeostasis and&#xD;
      eventually early, more targeted therapeutic interventions. The study will examine MRI changes&#xD;
      in patients, in their 5th decade of life, with high risk for the development of DISH (ie&#xD;
      diabetes mellitus, metabolic syndrome) compared with patients who don't have this risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient's selection- Patients will be recruited from obesity/metabolic/diabetes clinics and&#xD;
      from bariatric surgeries clinics. All patients will have the diagnosis of metabolic syndrome&#xD;
      National Cholesterol Education Panel III (NCEP). Patients in their 5th decade of life will be&#xD;
      recruited for the study. This study group will have to meet the NCEP 3 criteria for metabolic&#xD;
      syndrome and/or have type 2 diabetes mellitus (9). An age and sex matched individuals who do&#xD;
      not meet these pre-requisits will serve as a control group.&#xD;
&#xD;
      All asymptomatic patients will undergo postero-anterior and lateral x-rays of the thoracic&#xD;
      spine, unless they have postero-anterior or lateral thoracic spine or chest x-rays in the&#xD;
      year preceding the recruitment. For patients with back pain, addition of cervical or lumbar&#xD;
      spine radiographs will be permitted based on the physician judgement. Patients recruited for&#xD;
      the study will have a total spine and sacroiliac MRI (see below) read by radiologists and&#xD;
      rheumatologists, expert in musculoskeletal imaging, who will be blinded for the patient's&#xD;
      data. The readings of the radiographs and the MRI will be performed in a random order.&#xD;
&#xD;
      All patients and controls will undergo postero anterior and lateral thoracic spine X-rays and&#xD;
      MRI of the entire spine and their sacroiliac joints (Spine: sagittal T1-weighted and T2 with&#xD;
      fat suppression sequences, SIJ semicoronal T1-weighted and T2 with fat suppression sequences)&#xD;
      at study entry.&#xD;
&#xD;
      An accepted scoring system for the interpretation of the MRI studies will be employed for&#xD;
      both the spine and the sacroiliac joints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>case control study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Reader of the MRI studies will be blinded to the patients diagnoses</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory changes in the spine and/or sacroiliac joints</measure>
    <time_frame>6 months</time_frame>
    <description>inflammatory bone marrow edema lesions and fatty lesions and the anterior and posterior corners of the spine (Berlin score) as well as for the presence of enthesitis on the posterior elements.&#xD;
The sacroiliac joints will also be scored according to the Berlin scoring method for the presence of acute and structural inflammatory lesion, including BME, fat metaplasia, erosions, sclerosis, ankylosis. Anterior and posterior extraarticular enthesitis will also be registered</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hyperostosis, Diffuse Idiopathic Skeletal</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Thoracic spine x-rays+whole spine MRI</intervention_name>
    <description>PA radiographs of the thoracic spine and MRI of the whole spine and sacroiliac joints</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>study group</arm_group_label>
    <other_name>imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood tests</intervention_name>
    <description>blood chemistry including total cholesterol, LDL HDL, CBC, HbA1C, fasting glucose, TG, and insulin levels, HLA-B27, 2 vials of frozen serum for future studies.</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>study group</arm_group_label>
    <other_name>laboratory</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>constitutional and demographic data collection</intervention_name>
    <description>demographics, concomitant diseases (in particular type 2 DM, hypertension, hyperlipidemia) concomitant medications, height and weight (BMI), waist circumference</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>study group</arm_group_label>
    <other_name>data</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet the NCEP 3 criteria for metabolic syndrome and/or have type 2 diabetes mellitus&#xD;
             (9).&#xD;
&#xD;
        Age 40-49 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ESR and CRP levels above common levels adjusted for age, gender, and weight.(I have&#xD;
             ref for the determination of common CRP levels).&#xD;
&#xD;
        Positive HLA B-27 Personal or family history of Spondyloarthritis, psoriasis or&#xD;
        inflammatory arthritis (past or present) Inflammatory back pain as defined by the ASAS&#xD;
        definition (age at onset &lt;40y, insidious onset, improvement with exercise, no improvement&#xD;
        with rest, pain at night with improvement upon getting up = IBP if 4/5 items are present)&#xD;
        (Ref) History of uveitis Plain radiographs with evidence for DISH&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reuven Mader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HaEmek MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reuven Mader, MD</last_name>
    <phone>972-4-6494354</phone>
    <email>mader_r@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irina Novofastovski, MD</last_name>
    <phone>972-4-6494354</phone>
    <email>irina_no@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HaEmek MC and Chaim Sheba MC</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reuven Mader, MD</last_name>
      <phone>972-4-6494354</phone>
      <email>mader_r@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Irina Novofastovski, MD</last_name>
      <phone>972-4-6494354</phone>
      <email>Irina_no@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Irina Novofastovski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdallah Fawaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amir Bieber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iris Eshed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reuven Mader, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Mader R, Verlaan JJ, Buskila D. Diffuse idiopathic skeletal hyperostosis: clinical features and pathogenic mechanisms. Nat Rev Rheumatol. 2013 Dec;9(12):741-50. doi: 10.1038/nrrheum.2013.165. Epub 2013 Nov 5.</citation>
    <PMID>24189840</PMID>
  </reference>
  <reference>
    <citation>Mader R, Novofestovski I, Adawi M, Lavi I. Metabolic syndrome and cardiovascular risk in patients with diffuse idiopathic skeletal hyperostosis. Semin Arthritis Rheum. 2009 Apr;38(5):361-5. doi: 10.1016/j.semarthrit.2008.01.010. Epub 2008 Mar 4.</citation>
    <PMID>18304611</PMID>
  </reference>
  <reference>
    <citation>Mader R, Buskila D, Verlaan JJ, Atzeni F, Olivieri I, Pappone N, Di Girolamo C, Sarzi-Puttini P. Developing new classification criteria for diffuse idiopathic skeletal hyperostosis: back to square one. Rheumatology (Oxford). 2013 Feb;52(2):326-30. doi: 10.1093/rheumatology/kes257. Epub 2012 Sep 29.</citation>
    <PMID>23024057</PMID>
  </reference>
  <reference>
    <citation>Weiss BG, Bachmann LM, Pfirrmann CW, Kissling RO, Zubler V. Whole Body Magnetic Resonance Imaging Features in Diffuse Idiopathic Skeletal Hyperostosis in Conjunction with Clinical Variables to Whole Body MRI and Clinical Variables in Ankylosing Spondylitis. J Rheumatol. 2016 Feb;43(2):335-42. doi: 10.3899/jrheum.150162. Epub 2015 Dec 15.</citation>
    <PMID>26669910</PMID>
  </reference>
  <reference>
    <citation>Mader R, Novofastovski I, Iervolino S, Pavlov A, Chervinsky L, Schwartz N, Pappone N. Ultrasonography of peripheral entheses in the diagnosis and understanding of diffuse idiopathic skeletal hyperostosis (DISH). Rheumatol Int. 2015 Mar;35(3):493-7. doi: 10.1007/s00296-014-3190-0. Epub 2014 Dec 13.</citation>
    <PMID>25503650</PMID>
  </reference>
  <reference>
    <citation>Arad U, Elkayam O, Eshed I. Magnetic resonance imaging in diffuse idiopathic skeletal hyperostosis: similarities to axial spondyloarthritis. Clin Rheumatol. 2017 Jul;36(7):1545-1549. doi: 10.1007/s10067-017-3617-6. Epub 2017 Mar 31.</citation>
    <PMID>28364275</PMID>
  </reference>
  <reference>
    <citation>Julkunen H, Heinonen OP, Pyorala K. Hyperostosis of the spine in an adult population. Its relation to hyperglycaemia and obesity. Ann Rheum Dis. 1971 Nov;30(6):605-12. doi: 10.1136/ard.30.6.605. No abstract available.</citation>
    <PMID>5130140</PMID>
  </reference>
  <reference>
    <citation>8. Mader R, Fawaz A, Bieber A, Novofastovski I. Diffuse idiopathic skeletal hyperostosis (DISH) of young adults: lessons to be learnt. Austin J Orthopade &amp; Rheumatol. 2016; 3(4): 1043.</citation>
  </reference>
  <reference>
    <citation>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486. No abstract available.</citation>
    <PMID>11368702</PMID>
  </reference>
  <reference>
    <citation>Landewe RB, Hermann KG, van der Heijde DM, Baraliakos X, Jurik AG, Lambert RG, Ostergaard M, Rudwaleit M, Salonen DC, Braun J. Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment. J Rheumatol. 2005 Oct;32(10):2050-5.</citation>
    <PMID>16206369</PMID>
  </reference>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>July 30, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2017</study_first_posted>
  <last_update_submitted>August 6, 2022</last_update_submitted>
  <last_update_submitted_qc>August 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>HaEmek Medical Center, Israel</investigator_affiliation>
    <investigator_full_name>Reuven Mader</investigator_full_name>
    <investigator_title>Associate clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperostosis</mesh_term>
    <mesh_term>Hyperostosis, Diffuse Idiopathic Skeletal</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Other researchers are expected to perform the study in their own countries. If they perform the study, unidentified data from the present study will be processed with the other parties data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03237455
org study id: 0102-17-EMC
nct id: NCT03237455
lead sponsor: 
collaborator: 
is fda regulated drug: No
is fda regulated device: No
Diffuse idiopathic skeletal hyperostosis (DISH) is a poorly understood, systemic condition
      characterized by progressive calcification and ossification of ligaments and entheses. The
      current classification criteria allow diagnosing the disease in its late course, when
      significant bony overgrowth already involves the vertebral column and the appendicular
      skeleton. The research of the pathogenic mechanisms in DISH, is significantly hampered by the
      late diagnosis resulting from this definition.Based on recent MRI studies in both axial
      spondyloarthritis (axSpA) and in DISH, it seems that changes similar to the classical early
      inflammatory changes described in axSpA, can be detected in patients with DISH. We therefore
      hypothesize, that patients with metabolic syndrome without radiographic evidence for spinal
      DISH, might exhibit early MRI changes. If this hypothesis proves to be correct, early
      diagnosis and research of the possible pathogenetic mechanisms at this early stage might be
      very rewarding in investigations of the early aberrations of the entheses homeostasis and
      eventually early, more targeted therapeutic interventions. The study will examine MRI changes
      in patients, in their 5th decade of life, with high risk for the development of DISH (ie
      diabetes mellitus, metabolic syndrome) compared with patients who don't have this risk.
Patient's selection- Patients will be recruited from obesity/metabolic/diabetes clinics and
      from bariatric surgeries clinics. All patients will have the diagnosis of metabolic syndrome
      National Cholesterol Education Panel III (NCEP). Patients in their 5th decade of life will be
      recruited for the study. This study group will have to meet the NCEP 3 criteria for metabolic
      syndrome and/or have type 2 diabetes mellitus (9). An age and sex matched individuals who do
      not meet these pre-requisits will serve as a control group.

      All asymptomatic patients will undergo postero-anterior and lateral x-rays of the thoracic
      spine, unless they have postero-anterior or lateral thoracic spine or chest x-rays in the
      year preceding the recruitment. For patients with back pain, addition of cervical or lumbar
      spine radiographs will be permitted based on the physician judgement. Patients recruited for
      the study will have a total spine and sacroiliac MRI (see below) read by radiologists and
      rheumatologists, expert in musculoskeletal imaging, who will be blinded for the patient's
      data. The readings of the radiographs and the MRI will be performed in a random order.

      All patients and controls will undergo postero anterior and lateral thoracic spine X-rays and
      MRI of the entire spine and their sacroiliac joints (Spine: sagittal T1-weighted and T2 with
      fat suppression sequences, SIJ semicoronal T1-weighted and T2 with fat suppression sequences)
      at study entry.

      An accepted scoring system for the interpretation of the MRI studies will be employed for
      both the spine and the sacroiliac joints.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: case control study
primary purpose: Diagnostic
masking: Single (Outcomes Assessor)
masking description: Reader of the MRI studies will be blinded to the patients diagnoses
measure: Inflammatory changes in the spine and/or sacroiliac joints
time frame: 6 months
description: inflammatory bone marrow edema lesions and fatty lesions and the anterior and posterior corners of the spine (Berlin score) as well as for the presence of enthesitis on the posterior elements.
The sacroiliac joints will also be scored according to the Berlin scoring method for the presence of acute and structural inflammatory lesion, including BME, fat metaplasia, erosions, sclerosis, ankylosis. Anterior and posterior extraarticular enthesitis will also be registered
arm group label: study group
arm group type: Experimental
description: Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
arm group label: control group
arm group type: Active Comparator
description: Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
intervention type: Diagnostic Test
intervention name: Thoracic spine x-rays+whole spine MRI
description: PA radiographs of the thoracic spine and MRI of the whole spine and sacroiliac joints
arm group label: control group
arm group label: study group
other name: imaging
intervention type: Diagnostic Test
intervention name: blood tests
description: blood chemistry including total cholesterol, LDL HDL, CBC, HbA1C, fasting glucose, TG, and insulin levels, HLA-B27, 2 vials of frozen serum for future studies.
arm group label: control group
arm group label: study group
other name: laboratory
intervention type: Other
intervention name: constitutional and demographic data collection
description: demographics, concomitant diseases (in particular type 2 DM, hypertension, hyperlipidemia) concomitant medications, height and weight (BMI), waist circumference
arm group label: control group
arm group label: study group
other name: data
criteria: 
gender: All
minimum age: 40 Years
maximum age: 49 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Reuven Mader, MD
role: Principal Investigator
affiliation: HaEmek MC
last name: Reuven Mader, MD
phone: 972-4-6494354
email: mader_r@clalit.org.il
last name: Irina Novofastovski, MD
phone: 972-4-6494354
email: irina_no@clalit.org.il
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
investigator: 
investigator: 
investigator: 
investigator: 
country: Israel
citation: Mader R, Verlaan JJ, Buskila D. Diffuse idiopathic skeletal hyperostosis: clinical features and pathogenic mechanisms. Nat Rev Rheumatol. 2013 Dec;9(12):741-50. doi: 10.1038/nrrheum.2013.165. Epub 2013 Nov 5.
PMID: 24189840
citation: Mader R, Novofestovski I, Adawi M, Lavi I. Metabolic syndrome and cardiovascular risk in patients with diffuse idiopathic skeletal hyperostosis. Semin Arthritis Rheum. 2009 Apr;38(5):361-5. doi: 10.1016/j.semarthrit.2008.01.010. Epub 2008 Mar 4.
PMID: 18304611
citation: Mader R, Buskila D, Verlaan JJ, Atzeni F, Olivieri I, Pappone N, Di Girolamo C, Sarzi-Puttini P. Developing new classification criteria for diffuse idiopathic skeletal hyperostosis: back to square one. Rheumatology (Oxford). 2013 Feb;52(2):326-30. doi: 10.1093/rheumatology/kes257. Epub 2012 Sep 29.
PMID: 23024057
citation: Weiss BG, Bachmann LM, Pfirrmann CW, Kissling RO, Zubler V. Whole Body Magnetic Resonance Imaging Features in Diffuse Idiopathic Skeletal Hyperostosis in Conjunction with Clinical Variables to Whole Body MRI and Clinical Variables in Ankylosing Spondylitis. J Rheumatol. 2016 Feb;43(2):335-42. doi: 10.3899/jrheum.150162. Epub 2015 Dec 15.
PMID: 26669910
citation: Mader R, Novofastovski I, Iervolino S, Pavlov A, Chervinsky L, Schwartz N, Pappone N. Ultrasonography of peripheral entheses in the diagnosis and understanding of diffuse idiopathic skeletal hyperostosis (DISH). Rheumatol Int. 2015 Mar;35(3):493-7. doi: 10.1007/s00296-014-3190-0. Epub 2014 Dec 13.
PMID: 25503650
citation: Arad U, Elkayam O, Eshed I. Magnetic resonance imaging in diffuse idiopathic skeletal hyperostosis: similarities to axial spondyloarthritis. Clin Rheumatol. 2017 Jul;36(7):1545-1549. doi: 10.1007/s10067-017-3617-6. Epub 2017 Mar 31.
PMID: 28364275
citation: Julkunen H, Heinonen OP, Pyorala K. Hyperostosis of the spine in an adult population. Its relation to hyperglycaemia and obesity. Ann Rheum Dis. 1971 Nov;30(6):605-12. doi: 10.1136/ard.30.6.605. No abstract available.
PMID: 5130140
citation: 8. Mader R, Fawaz A, Bieber A, Novofastovski I. Diffuse idiopathic skeletal hyperostosis (DISH) of young adults: lessons to be learnt. Austin J Orthopade & Rheumatol. 2016; 3(4): 1043.
citation: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486. No abstract available.
PMID: 11368702
citation: Landewe RB, Hermann KG, van der Heijde DM, Baraliakos X, Jurik AG, Lambert RG, Ostergaard M, Rudwaleit M, Salonen DC, Braun J. Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment. J Rheumatol. 2005 Oct;32(10):2050-5.
PMID: 16206369
responsible party type: Principal Investigator
investigator affiliation: HaEmek Medical Center, Israel
investigator full name: Reuven Mader
investigator title: Associate clinical professor
mesh term: Hyperostosis
mesh term: Hyperostosis, Diffuse Idiopathic Skeletal
mesh term: Metabolic Syndrome
sharing ipd: No
ipd description: Other researchers are expected to perform the study in their own countries. If they perform the study, unidentified data from the present study will be processed with the other parties data.